SCHEMBL12414652

SCHEMBL12414652

CC(C)c1ncc(N2CCCC2=O)cc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 1/20 0.40
PARP1 P09874 1/20 0.39
CCR6 P51684 1/20 0.39
LMNA P02545 1/20 0.39
AKR1C3 P42330 2/20 0.39
ALOX5AP P20292 2/20 0.38
FEN1 P39748 1/20 0.38
FFAR1 O14842 2/20 0.38
HRH3 Q9Y5N1 3/20 0.37
HRH1 P35367 1/20 0.37
ALDH1A1 P00352 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2D6 P10635 1/20 0.37
CYP2C9 P11712 1/20 0.37
HPGD P15428 1/20 0.37
CYP2C19 P33261 1/20 0.37
CYP11B2 P19099 1/20 0.37
FFAR4 Q5NUL3 1/20 0.36
EGLN2 Q96KS0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13003536 0.81 LMNA (0.44) HTR6LMNAAKR1C3ALDH1A1CYP1A2
SCHEMBL12414656 0.76 AKR1C3 (0.43) HTR6CCR6LMNAAKR1C3HRH3
SCHEMBL24307804 0.76 HTR6 (0.44) HTR6LMNAAKR1C3ALOX5APFEN1
SCHEMBL12414664 0.75 ACACB (0.43) PARP1HRH3CYP1A2CYP2C9CYP11B2
SCHEMBL21317455 0.72 CCR6 (0.54) HTR6CCR6LMNAALDH1A1CYP1A2
SCHEMBL21509722 0.72 AKR1C3 (0.49) CCR6AKR1C3HRH3HRH1ALDH1A1
SCHEMBL17384714 0.72 LMNA (0.54) LMNAAKR1C3ALDH1A1CYP1A2CYP3A4
SCHEMBL14236720 0.72 LMNA (0.49) LMNAAKR1C3ALDH1A1CYP1A2CYP3A4
SCHEMBL14525386 0.72 AKR1C3 (0.42) HTR6LMNAAKR1C3HRH3ALDH1A1
SCHEMBL18488460 0.71 ALDH1A1 (0.45) PARP1LMNAAKR1C3ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-8293729-B2 Compounds, pharmaceutical composition and methods relating thereto BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-23 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166116-A1 NEW COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS RELATING THERETO MC2R, REN, CYP11B2 HTR6 1078/4885PARP1 1230/4885CCR6 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.